New bioengineered strategy shows potential for treating ulcerative colitis

By taking advantage of mechanisms that allow cancer cells to evade immune attack, UT Southwestern Medical Center researchers have developed a new strategy in animal models that has potential for treating ulcerative colitis.

NephroDI Therapeutics, MSRD partner to develop therapy for NDI

NephroDI Therapeutics’ NDI-5001 is being developed to treat X-linked congenital nephrogenic diabetes insipidus, a rare genetic kidney condition. Credit: crystal light / Shutterstock.com. NephroDI Therapeutics

June 23, 2023

Quest Diagnostics & Ultima Team Up to Tackle MRD & Whole Genome Sequencing

What You Should Know: Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics, the nation’s leading provider of diagnostic information services,

January 9, 2024

Cantourage Group SE (von NuWays AG) – Biotech Investments

Original-Research: Cantourage Group SE – von NuWays AG Einstufung von NuWays AG zu Cantourage Group SE Unternehmen: Cantourage Group SE ISIN: DE000A3DSV01 Anlass der Studie:

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.